Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society..
In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of the Pediatric Infectious Diseases Society - 12(2023), 4 vom: 28. Apr., Seite 234-238 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simões, Eric A F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 11.05.2023 Date Revised 13.12.2023 published: Print ClinicalTrials.gov: NCT04816643 Citation Status MEDLINE |
|---|
| doi: |
10.1093/jpids/piad015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354347012 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354347012 | ||
| 003 | DE-627 | ||
| 005 | 20231227131150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jpids/piad015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM354347012 | ||
| 035 | |a (NLM)36929216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simões, Eric A F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04816643 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. | ||
| 520 | |a In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162b2 vaccine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a booster | |
| 650 | 4 | |a children | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 700 | 1 | |a Klein, Nicola P |e verfasserin |4 aut | |
| 700 | 1 | |a Sabharwal, Charu |e verfasserin |4 aut | |
| 700 | 1 | |a Gurtman, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Kitchin, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Ukkonen, Benita |e verfasserin |4 aut | |
| 700 | 1 | |a Korbal, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xuping |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Uzma N |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Lockhart, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Cunliffe, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Kena A |e verfasserin |4 aut | |
| 700 | 1 | |a Koury, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Pei-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David |e verfasserin |4 aut | |
| 700 | 1 | |a Türeci, Ӧzlem |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Kathrin U |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, William C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Pediatric Infectious Diseases Society |d 2012 |g 12(2023), 4 vom: 28. Apr., Seite 234-238 |w (DE-627)NLM227436326 |x 2048-7207 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4 |g day:28 |g month:04 |g pages:234-238 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jpids/piad015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4 |b 28 |c 04 |h 234-238 | ||